文献速递消化系统肿瘤

Wee1抑制剂Adavosertib联合吉西他滨与放疗在局部晚期胰腺癌中的剂量递增试验

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
PubMed 文献 · J Clin Oncol · 2019-08-09

推荐II期剂量为AZD1775 150 mg/d,8例(24%)出现剂量限制性毒性,中位总生存21.7个月(90%CI 16.7–24.8),中位无进展生存9.4个月(90%CI 8.0–9.9)。

要点

  • AZD1775联合吉西他滨与放疗的推荐II期剂量为150 mg/d。
  • 24%患者出现剂量限制性毒性,常见厌食、恶心或乏力。
  • 中位总生存21.7个月,中位无进展生存9.4个月。

核心结论

  • AZD1775联合吉西他滨与放疗在产生替代组织靶点结合的剂量下耐受良好。
  • 总生存显著高于既往吉西他滨联合放疗的结果,值得进一步研究。

研究设计与样本

  • 剂量递增试验,采用基于事件时间的持续重新评估方法,依据治疗前15周内剂量限制性毒性发生率调整剂量。

主要发现

  • 8例患者(24%)发生剂量限制性毒性,最常见为厌食、恶心或疲劳。
  • 所有患者中位总生存21.7个月(90%CI 16.7至24.8个月),中位无进展生存9.4个月(90%CI 8.0至9.9个月)。
  • 毛囊活检显示推荐II期剂量AZD1775给药后,免疫组化检测的磷酸化细胞周期蛋白依赖性激酶1染色降低,提示Wee1抑制。

关键数值与推荐

  • 推荐II期剂量AZD1775为150 mg/d。
  • 吉西他滨剂量为1,000 mg/m2,第1天和第8天给药。
  • AZD1775每日一次,第1、2、8、9天给药,每21天为一周期。

临床怎么用

  • 在局部晚期胰腺癌中,AZD1775 150 mg/d可联合吉西他滨1,000 mg/m2(第1、8天)及放疗使用。
  • 治疗期间需监测剂量限制性毒性,常见厌食、恶心和乏力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with gemcitabine and radiation in patients with newly diagnosed locally advanced pancreatic cancer. PATIENTS AND METHODS: Thirty-four patients with locally advanced pancreatic cancer were enrolled with the intention to receive four 21-day cycles of gemcitabine (1,000 mg/m2 days 1 and 8) with AZD1775 (once daily on days 1, 2, 8, and 9). Cycles 2 and 3 were administered concurrently with radiation, and cycles 5 to 8 were optional. AZD1775 was dose escalated using a time-to-event continual reassessment method on the basis of the rate of dose-limiting toxicities within the first 15 weeks of therapy. The primary objective was to determine the maximum tolerated dose of AZD1775 given in conjunction with gemcitabine and radiation. Secondary objectives were to estimate overall and progression-free survival and determine pharmacodynamic activity of AZD1775 in surrogate tissues. RESULTS: The recommended phase II dose of AZD1775 was 150 mg/d. Eight patients (24%) experienced a dose-limiting toxicity, most commonly anorexia, nausea, or fatigue. The median overall survival for all patients was 21.7 months (90% CI, 16.7 to 24.8 months), and the median progression-free survival was 9.4 months (90% CI, 8.0 to 9.9 months). Hair follicle biopsy samples demonstrated evidence of Wee1 inhibition with decreased phosphorylation of cyclin-dependent kinase 1 staining by immunohistochemistry after AZD1775 administration at the recommended phase II dose. CONCLUSION: AZD1775 in combination with gemcitabine and radiation therapy was well tolerated at a dose that produced target engagement in a surrogate tissue. The overall survival is substantially higher than prior results combining gemcitabine with radiation therapy and warrants additional investigation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cuneo KC, Morgan MA, Sahai V, et al. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. J Clin Oncol. 2019. PMID: 31398082. doi:10.1200/JCO.19.00730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。